摘要
对于胃癌患者,临床上大多选择化疗方案,但该治疗方案往往会使患者出现毒副反应,以至于其使用范围受限,无法有效提升患者远期疗效。靶向治疗属于一种新型治疗手段,已在实体瘤患者、血液肿瘤患者中得到应用,并且逐步拓展至胃癌患者临床治疗中。鉴于此,笔者以胃癌靶向药物的临床治疗进展作为本文的讨论对象,分别从EGFR抑制剂、mTOR抑制剂和c-Met激酶抑制剂等方面进行分析,以期进一步优化胃癌靶向药物的临床治疗程序,从而为胃癌患者提供更加优质的临床服务。
For patients with gastric cancer,most of them choose clinical chemotherapy,but it often cause side effects in patients,which lead its usage limited,and can not effectively enhance on patient long-term effect.Targeted therapy is a new method that has been used in patients with solid tumors,blood cancer patients,and even gradually expand to the clinical treatment of patients with gastric cancer.In view of this,the author takes the remedial proceeding of gastric cancer targeted drugs as the key projects of this study were analysed from EGFR inhibitors,mTOR inhibitors,and c-Met kinase inhibitor,etc.,we look forward to further optimize gastric cancer targeted drugs clinical procedures,so as to provide a growing quality clinical services for patients with gastric cancer.
出处
《生物化工》
2016年第1期76-78,共3页
Biological Chemical Engineering
